Background:
- Recent advances in cancer research have led to new therapies to treat the disease. It
is important to continue these advances and discover new ones. To do that, researchers
need tissue samples from solid tumors. This study will collect such samples from people
already scheduled to have a procedure at the National Institutes of Health Clinical
Center (NIHCC).
Objectives:
- To collect tissue samples for use in studying new ways to treat tumors.
Eligibility:
- Adults 18 years and older, with a precancerous or cancerous solid tumor who are
scheduled to have surgery or a biopsy at the NIHCC.
- Children under the age of 18 but who are older than 2 years of age are eligible to
be enrolled on the research sample collection portion of this study if they will
have a biopsy or surgery as part of their medical care.
Design:
- Before their procedure, participants will have a small blood sample taken.
- Some participants will undergo leukapheresis. In this procedure, blood is removed
through a tube in one arm and circulated through a machine that removes white blood
cells. The blood, minus the white blood cells, is returned through a tube in the
other arm. The procedure takes 3-4 hours.
- For all participants, during the surgery or biopsy, pieces of the tumor and pieces
of normal tissue near it will be removed for this study. The rest of the tumor or
precancerous growth will be sent to a lab for analysis.
- Participants will return to the clinic about 6 weeks after the operation for a
routine checkup. Some may have to return for additional follow-up.
Additional locations may be listed on ClinicalTrials.gov for NCT01915225.
Locations matching your search criteria
United States
Maryland
Bethesda
National Institutes of Health Clinical CenterStatus: Active
Contact: NIH Clinical Center
Phone: 866-820-4505
Background:
Recent advances and insights into the molecular pathogenesis of cancer have led to the
development of novel molecular and biologic targeted therapies for the treatment of
advanced cancer patients. A critical challenge in extending these studies involves the
identification and validation of new therapeutic targets for future cancer therapies.
As Surgical Oncologists at the NCI, we have an interest in identifying novel molecular
and biologic targets to facilitate the development of future cancer therapies. In
addition, we have the primary responsibility for providing surgical consultative services
to the NIH. As such, we are uniquely positioned to acquire and perform important studies
on solid tumor tissue to help identify therapeutic targets that may have significant
clinical ramifications.
Objective:
To collect biologic samples from participants undergoing diagnostic, preventative, or
therapeutic interventions for premalignant, primary or metastatic solid tumors for the
purpose of identifying novel molecular and biologic therapeutic targets.
Eligibility:
Participants age >= 2 years and older with radiographic or clinical suspicion of, genetic
predisposition for, biochemical evidence of, or histologically/cytologically proven solid
neoplasms who require diagnostic, preventative, or therapeutic intervention as a part of
the diagnosis and/or treatment and/or follow up for their neoplasm. Note: Participants >=
2 years of age and under 18 years of age may only participate in research sample
collection if the tissue acquisition is performed during a clinically indicated surgical
procedure, and the biospecimen sampling (resected tumor tissue, blood, urine, ascites, or
bile) does not add risk to the clinically indicated procedures.
Participants without solid tumors in whom a diagnostic, preventative, or therapeutic
intervention is being performed, but for whom surgical quality and safety outcomes data
are generated.
Participants should have laboratory and physical examination parameters within acceptable
limits by standard of practice guidelines prior to planned intervention.
Design:
A tissue acquisition trial in which tissues will be obtained at the time of intervention.
No investigational therapy will be given.
It is anticipated that 1,764 participants will be followed on this study.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationNational Cancer Institute
Principal InvestigatorJeremy L Davis
